Agilent Technologies

Agilent Technologies, Inc. is a global leader in analytical and clinical laboratory technologies, providing instruments, software, services, and consumables that deliver trusted answers to customers' most challenging questions in life sciences, diagnostics, and applied chemical markets. Headquartered in Santa Clara, California, Agilent serves analytical laboratories and clinical diagnostics markets worldwide with approximately 18,000 employees.

Created in 1999 as a spin-off from Hewlett-Packard Company, Agilent's founding represents one of the largest initial public offerings in Silicon Valley history. On November 18, 1999, the company raised $2.1 billion in its IPO—a remarkable contrast to the $538 in working capital that HP founders Bill Hewlett and Dave Packard began with in 1938. The spin-off included HP's test and measurement, semiconductor, chemical analysis, and healthcare businesses. Agilent became fully independent on June 2, 2000, when HP distributed its Agilent shares to HP shareholders.

On May 1, 2024, Padraig McDonnell became Agilent's fourth CEO, succeeding Mike McMullen who retired after nearly 40 years with the company. McDonnell, who has been in the analytical and scientific instrument industry for over 25 years (starting at HP in 1998), brings extensive operational and commercial experience from his previous roles as president of the Agilent CrossLab Group and chief commercial officer.

Agilent's business is organized into three segments: Life Sciences and Diagnostics Markets ($3.22 billion in FY2024, 49% of revenue), Diagnostics and Genomics ($1.65 billion, 25%), and Agilent CrossLab ($1.64 billion, 25%). The company's comprehensive portfolio includes gas and liquid chromatography, mass spectrometry, spectroscopy, genomics, cell analysis, automation, informatics, and a broad range of consumables and services.

Fiscal year 2025 has shown strong recovery with full-year revenue projected at $6.73-$6.81 billion (3.4-4.6% growth). Fourth quarter 2025 revenue was $1.86 billion, representing 9.4% reported growth and 7.2% core growth. The Life Sciences and Diagnostics Markets Group showed particularly strong performance with 15% reported growth (11% core) in Q4 2025, driven by pharmaceutical and biopharma customers. With major acquisitions like Varian in 2011 ($1.5 billion) and Dako in 2012 ($2.2 billion), plus the 2014 spin-off of its electronic measurement business as Keysight Technologies, Agilent has strategically focused on becoming the premier provider of life sciences and diagnostics solutions.